Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$528.51M
EBITDA Margin
1.18%
TTM Avg
-15.78%
3Y Avg
-775.36%
5Y Avg
-845.24%
Market Cap
$527.92M
EBITDA Margin
-17741.55%
TTM Avg
-126136.56%
3Y Avg
-126136.56%
5Y Avg
-126136.56%
Market Cap
$516.91M
EBITDA Margin
-230187.80%
TTM Avg
-372428.90%
3Y Avg
-255754.79%
5Y Avg
-154022.75%
Market Cap
$535.00M
EBITDA Margin
-4782.00%
TTM Avg
-3061.67%
3Y Avg
-6701.43%
5Y Avg
-4552.91%
Market Cap
$513.77M
EBITDA Margin
-970.11%
TTM Avg
-861.99%
3Y Avg
-583.02%
5Y Avg
-735.09%
Market Cap
$539.20M
EBITDA Margin
-91.00%
TTM Avg
-295.88%
3Y Avg
-8346.66%
5Y Avg
-8346.66%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | $527.68M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $528.51M | 1.18% | -15.78% | -775.36% | -845.24% |
| ProKidney Corp. (PROK)vs › | $527.92M | -17741.55% | -126136.56% | -126136.56% | -126136.56% |
| Immix Biopharma, Inc. (IMMX)vs › | $528.58M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.91M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
| Shattuck Labs, Inc. (STTK)vs › | $535.00M | -4782.00% | -3061.67% | -6701.43% | -4552.91% |
| Monopar Therapeutics Inc. (MNPR)vs › | $538.98M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $513.77M | -970.11% | -861.99% | -583.02% | -735.09% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $539.20M | -91.00% | -295.88% | -8346.66% | -8346.66% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $512.70M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
